Staphylococcus aureus prosthetic joint infection
Phaxiam Therapeutics focuses on hip and knee prosthetic joint infection linked to Staphylococcus aureus, with particular interest in cases managed with DAIR and suppressive antibiotic therapy. Its research activity includes clinical evaluation of bacteriophage therapy alongside standard infection management.
- Prosthetic joint infection
- DAIR
- Suppressive antibiotic therapy
The sponsor’s work in this area is centered on difficult-to-treat joint infections where implant preservation remains clinically important.
Infectious endocarditis
The sponsor is also active in Staphylococcus aureus endocarditis, reflecting a therapeutic interest in serious cardiovascular infection and pathogen-targeted treatment strategies. This area extends its infectious disease portfolio beyond orthopedic infection into invasive systemic disease.
- Staphylococcus aureus endocarditis
- Cardiovascular infection
- Systemic bacterial infection
Research in this field addresses a high-risk infection setting where improved antimicrobial approaches are clinically relevant.
Urinary tract infection
Phaxiam Therapeutics includes bacterial urinary infection in its clinical research landscape, with attention to E. coli-associated urinary tract infection. This indicates involvement in common community and hospital infection settings where targeted anti-infective strategies are being explored.
- Bacterial urinary infection
- E. coli
- Urinary tract infection
The sponsor’s interest in this domain complements its work on invasive and device-related infections.
Bacteriophage-based anti-infective therapy
Across its trials, the company’s main therapeutic emphasis lies in bacteriophage therapy for bacterial infection, particularly infections caused by Staphylococcus aureus and Escherichia coli. This includes research in settings where conventional treatment options are limited by persistent infection or implanted medical devices.
- Bacteriophage therapy
- Bacterial infection
- Device-related infection
Its clinical portfolio is concentrated in infectious diseases requiring pathogen-focused therapeutic development.
